Gristick HB, Hartweger H, Loewe M, van Schooten J, Ramos V, Oliveira TY, Nishimura Y, Koranda NS, Wall A, Yao K-H et al..  2023.  CD4 binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wild-type animals.. Sci Immunol. 8(80):eade6364.

Reed JC, Westergreen N, Barajas BC, Ressler DTB, Phuong DJ, Swain JV, Lingappa VR, Lingappa JR.  2018.  Formation of RNA Granule-Derived Capsid Assembly Intermediates Appears To Be Conserved between Human Immunodeficiency Virus Type 1 and the Nonprimate Lentivirus Feline Immunodeficiency Virus.. J Virol. 92(9)

Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H et al..  2017.  Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.. Sci Transl Med. 9(373)

Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens A-J, Ozorowski G et al..  2017.  Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.. J Exp Med. 214(9):2573-2590.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE et al..  2017.  HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.. PLoS Med. 14(11):e1002417.

Zhen A, Rezek V, Youn C, Lam B, Chang N, Rick J, Carrillo M, Martin H, Kasparian S, Syed P et al..  2017.  Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.. J Clin Invest. 127(1):260-268.

Feelixge HSDe Silva, Stone D, Pietz HL, Roychoudhury P, Greninger AL, Schiffer JT, Aubert M, Jerome KR.  2016.  Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy.. Antiviral Res. 126:90-8.

Lu C-L, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, Horwitz JA, Nogueira L, Golijanin J, Gazumyan A et al..  2016.  Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.. Science. 352(6288):1001-4.

Halper-Stromberg A, Nussenzweig MC.  2016.  Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.. J Clin Invest. 126(2):415-23.

Kim SG, Lowe EL, Dixit D, Youn CSeyeon, Kim IJ, Jung JB, Rovner R, Zack JA, Vatakis DN.  2015.  Cocaine-mediated impact on HIV infection in humanized BLT mice.. Sci Rep. 5:10010.

Nixon CC, Vatakis DN, Reichelderfer SN, Dixit D, Kim SG, Uittenbogaart CH, Zack JA.  2013.  HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice.. Blood. 122(13):2195-204.

Kitchen SG, Levin BR, Bristol G, Rezek V, Kim S, Aguilera-Sandoval C, Balamurugan A, Yang OO, Zack JA.  2012.  In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells.. PLoS Pathog. 8(4):e1002649.

Zhang L, Lewin SR, Markowitz M, Lin HH, Skulsky E, Karanicolas R, He Y, Jin X, Tuttleton S, Vesanen M et al..  1999.  Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy.. J Exp Med. 190(5):725-32.

Zhang L, Huang Y, Yuan H, Tuttleton S, Ho DD.  1997.  Genetic characterization of vif, vpr, and vpu sequences from long-term survivors of human immunodeficiency virus type 1 infection.. Virology. 228(2):340-9.